Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ZYME
Zymeworks Inc.
stock NASDAQ

At Close
Sep 4, 2025 3:59:56 PM EDT
14.06USD-0.566%(-0.08)428,683
14.05Bid   14.08Ask   0.03Spread
Pre-market
Sep 2, 2025 9:28:30 AM EDT
13.46USD-4.809%(-0.68)0
After-hours
Sep 4, 2025 4:00:30 PM EDT
14.08USD+0.142%(+0.02)2,631
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
12:05PM EST  Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares   Business Wire
Jan 27, 2022
11:59AM EST  Canadian biotech company, Zymeworks Inc. (ZYME), saw its stock drop another 4% on t5he Thursday market as the company announced the offering of $100 million worth of stock.   RTTNews
07:58AM EST  The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study   Benzinga
Jan 26, 2022
09:57PM EST  Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, said that it has priced its underwritten public offering of 9.16 million common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3.34 million common shares.   RTTNews
09:36PM EST  Zymeworks Announces Pricing of $100.0 Million Public Offering   Business Wire
04:19PM EST  Zymeworks Announces Proposed Public Offering; No Terms Disclosed   Benzinga
04:01PM EST  Zymeworks Announces Proposed Public Offering   Business Wire
Jan 20, 2022
08:28AM EST  The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug   Benzinga
07:03AM EST  Zymeworks To Cut Its Workforce By Almost 25%, Outlines 2022 & 2023 Priorities   Benzinga
Jan 19, 2022
04:18PM EST  Zymeworks Offers 2022 Strategic Priorities, Outlook   Benzinga
04:15PM EST  Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022   Business Wire
Jan 15, 2022
08:30AM EST  Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule   Business Wire
Jan 10, 2022
06:07AM EST  ALX Oncology Provides Corporate Update And Highlights Key Milestones In 2022   Benzinga
06:00AM EST  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2022.   GlobeNewswire Inc
Jan 6, 2022
08:30AM EST  Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference   Business Wire
Jan 5, 2022
04:31PM EST  Zymeworks Names Kenneth Galbraith As Chair, CEO   Benzinga
04:30PM EST  Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani   Business Wire
Dec 10, 2021
12:41PM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021   Benzinga
07:55AM EST  Raymond James Downgrades Zymeworks to Outperform, Announces $74 Price Target   Benzinga
06:14AM EST  SVB Leerink Upgrades Zymeworks to Outperform   Benzinga
Dec 9, 2021
09:47PM EST  Zymeworks Announces Expansion Of Zanidatamab Pivotal Trial In Asia In Collaboration With BeiGene And Associated $8M Milestone Payment   Benzinga
Dec 8, 2021
06:00PM EST  Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer   Business Wire
08:19AM EST  The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom   Benzinga
Dec 6, 2021
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Dec 1, 2021
08:34AM EST  Zymeworks:Janssen Bispecific Antibody To Begin Clinical Development Utilizing Azymetric And EFECT Therapeutic Platforms   RTTNews
08:34AM EST  Zymeworks Reports Its Second J&J's Janssen Bispecific Antibody To Begin Clinical Development Utilizing Azymetric, EFFECT Therapeutic Platforms   Benzinga
08:30AM EST  Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric(tm) and EFECT(tm) Therapeutic Platforms   Business Wire
Nov 19, 2021
09:24AM EST  Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Breast Cancer To Be Presented At San Antonio Breast Cancer Symposium (SABCS) Dec. 7-10   Benzinga
09:23AM EST  Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Breast Cancer   RTTNews
09:21AM EST  Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)   Business Wire
Nov 10, 2021
06:46AM EST  SVB Leerink Maintains Market Perform on Zymeworks, Lowers Price Target to $27   Benzinga
Nov 9, 2021
04:06PM EST  Zymeworks Names Neil Josephson, M.D., Chief Medical Officer   Business Wire
11:47AM EST  Zymeworks Launches Global Phase 3 Zanidatamab Trial In First-Line HER2Positive Gastroesophageal Adenocarcinoma   Benzinga
08:30AM EST  Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2?Positive Gastroesophageal Adenocarcinoma (GEA)   Business Wire
Nov 8, 2021
04:15PM EST  Zymeworks to Present at Upcoming Investor Conferences   Business Wire
Nov 4, 2021
06:27AM EDT  SVB Leerink Maintains Market Perform on Zymeworks, Lowers Price Target to $28   Benzinga
Nov 3, 2021
06:32PM EDT  Zymeworks Q3 EPS $(1.25) Up From $(1.43) YoY, Sales $4.39M Up From $2.64M YoY   Benzinga
04:15PM EDT  Zymeworks Reports 2021 Third Quarter Financial Results   Business Wire
Oct 26, 2021
05:30AM EDT  Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers   Business Wire
Oct 5, 2021
08:38AM EDT  Zymeworks : First Patient Dosed In Phase 1b/2 Trial Of Zanidatamab & Evorpacept In Breast Cancer And Other Solid Tumors   RTTNews
08:36AM EDT  Zymeworks And ALX Oncology Announce First Patient Dosed In Phase 1b/2 Clinical Trial Of Zanidatamab And Evorpacept (ALX148) In Patients With Advanced HER2-Expressing Breast Cancer And Other Solid Tumors   Benzinga
Oct 1, 2021
04:52PM EDT  Zymeworks Files For Mixed Shelf; Size Not Disclosed   Benzinga
Sep 17, 2021
10:05AM EDT  UPDATE: Dealreporter On Zymeworks Notes Co. Phase 2 Trial Data On Gastroesophageal Adenocarcinoma Candidate 'Could Intensify Potential Sale Talks,' Cites Jul. 1, 2021 Report Co. Was Exploring Potential Sale Following A Takeover Approach   Benzinga
Sep 16, 2021
06:00AM EDT  Zymeworks Says Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate   RTTNews
05:30AM EDT  Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress   Business Wire
Sep 12, 2021
06:50PM EDT  Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress   Business Wire
Aug 5, 2021
06:47AM EDT  HC Wainwright & Co. Maintains Buy on Zymeworks, Lowers Price Target to $44   Benzinga
Aug 4, 2021
05:25PM EDT  Zymeworks Q2 EPS $(1.31) Down From $(0.77) YoY, Sales $1.77M Down From $12.36M YoY   Benzinga
04:15PM EDT  Zymeworks Reports 2021 Second Quarter Financial Results   Business Wire
Aug 3, 2021
08:33AM EDT  UPDATE: Zymeworks Received Upfront Payment Of $50M, Is Eligible To Potentially Receive Up To $282M In Development, Up To $1.12B In Commercial Milestone Payments   Benzinga
08:33AM EDT  Zymeworks Reports Milestone Payment As J&J's Janssen Achieves First Patient Dosed For Bispecific Antibody Utilizing Zymeworks' Azymetric, EFECT Therapeutic Platforms   Benzinga
08:30AM EDT  Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks' Azymetric(tm) and EFECT(tm) Therapeutic Platforms   Business Wire
Jul 28, 2021
08:36AM EDT  Zymeworks Announces First Patient With Advanced HER2-Positive Breast Cancer Dosed With Zanidatamab In Combination With Tukysa And Chemotherapy   Benzinga
08:36AM EDT  Zymeworks Doses First Patient With HER2-Positive Breast Cancer With Zanidatamab With Tukysa And Chemotherapy   RTTNews
08:30AM EDT  Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa(r) (Tucatinib) and Chemotherapy   Business Wire
Jul 26, 2021
11:28AM EDT  Zymeworks Option Alert: Sep 17 $45 Calls at the Ask: 540 @ $2.23 vs 13 OI; Earnings 8/9 After Close [est] Ref=$33.71   Benzinga
Jul 8, 2021
08:30AM EDT  Zymeworks to Present at Ladenburg Thalmann Healthcare Conference   Business Wire
May 26, 2021
08:30AM EDT  Zymeworks to Present at Jefferies Virtual Healthcare Conference   Business Wire
May 7, 2021
07:29AM EDT  HC Wainwright & Co. Maintains Buy on Zymeworks, Lowers Price Target to $55   Benzinga
May 6, 2021
08:30AM EDT  Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting   Business Wire
May 5, 2021
04:56PM EDT  Zymeworks Q1 EPS $(0.87) Down From $(0.64) YoY, Sales $644.00K Down From $8.27M YoY   Benzinga
04:15PM EDT  Zymeworks Reports 2021 First Quarter Financial Results   Business Wire
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
11:05AM EDT  Stock Alert: Zymeworks Down 7%   RTTNews
08:45AM EDT  Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join   GlobeNewswire Inc
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 19, 2021
08:30AM EDT  Zymeworks Announces Succession Plan for Chief Medical Officer   Business Wire
Apr 14, 2021
07:51AM EDT  The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead   Benzinga
Apr 13, 2021
08:30AM EDT  Zymeworks to Present at Bloom Burton Healthcare Conference   Business Wire
Apr 12, 2021
10:11AM EDT  Zymeworks Saturday Morning Showcased Preclinical Assets, Including New Therapeutic Platform, ProTECT, And Zanidatamab Mechanisms Of Action At American Association For Cancer Research Conference   Benzinga
Apr 10, 2021
08:30AM EDT  Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT(tm), and Zanidatamab Mechanisms of Action at AACR Annual Meeting   Business Wire
Mar 31, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021   Benzinga
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
07:15AM EDT  Credit Suisse Initiates Coverage On Zymeworks with Outperform Rating, Announces Price Target of $55   Benzinga
Mar 10, 2021
05:27PM EST  Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021   Business Wire
Feb 25, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2021   Benzinga
06:50AM EST  SVB Leerink Downgrades Zymeworks to Market Perform, Lowers Price Target to $41   Benzinga
Feb 24, 2021
04:53PM EST  Zymeworks Q4 EPS $(0.74) Up From $(1.06) YoY, Sales $15.68M Up From $1.88M YoY   Benzinga
04:15PM EST  Zymeworks Reports 2020 Year-End Financial Results   Business Wire
Feb 10, 2021
04:15PM EST  Zymeworks to Participate in Upcoming Investor Conferences and Events   Business Wire
Feb 9, 2021
04:30PM EST  Zymeworks Expands Commercial Team and Creates New R&D Role   Business Wire
Feb 8, 2021
06:44AM EST  HC Wainwright & Co. Assumes Zymeworks at Buy, Announces Price Target of $57   Benzinga
Jan 28, 2021
08:03AM EST  The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO   Benzinga
Jan 27, 2021
05:15PM EST  Zymeworks Reports Has Begun Enrolling Patients Into Expansion Cohort Portion Of Ongoing Phase 1 Trial For ZW49   Benzinga
05:15PM EST  Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development   Business Wire
07:36AM EST  The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement   Benzinga
Jan 25, 2021
12:28PM EST  Zymeworks shares were trading higher after Citigroup downgraded the stock from Buy to Neutral.   Benzinga
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 25, 2021   Benzinga
09:35AM EST  Citigroup Downgrades Zymeworks to Neutral, Raises Price Target to $53   Benzinga
Jan 23, 2021
09:14AM EST  The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More   Benzinga
Jan 19, 2021
08:37AM EST  Raymond James Maintains Strong Buy on Zymeworks, Raises Price Target to $74   Benzinga
Jan 15, 2021
08:36AM EST  Zymeworks Announces Updated Zanidatamab Data To Be Presented At ASCO Jan. 15-17   Benzinga
08:35AM EST  Zymeworks Says New And Updated Clinical Data For The HER2?targeted Bispecific Antibody Zanidatamab   RTTNews
08:31AM EST  Zanidatamab Data Highlight Durable Antitumor Activity in HER2?Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium   Business Wire
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 12, 2021
07:07AM EST  SVB Leerink Maintains Outperform on Zymeworks, Raises Price Target to $66   Benzinga
Jan 11, 2021
08:01AM EST  Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities   Business Wire
Jan 9, 2021
01:02PM EST  The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off   Benzinga
Jan 7, 2021
08:30AM EST  Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49   Business Wire
Dec 10, 2020
08:35AM EST  Zanidatamab Clinical Data Selected For Oral Presentation At American Society Of Clinical Oncology Gastrointestinal Cancers Symposium   Benzinga
08:30AM EST  Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium   Business Wire
Dec 2, 2020
08:00AM EST  Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application   Business Wire
Dec 1, 2020
08:36AM EST  Zymeworks Announces Expansion Of Zanidatamab Pivotal Trial In HER2-Amplified Biliary Tract Cancer In Asia   RTTNews
08:32AM EST  Zymeworks Announces Expansion of Zanidatamab Pivotal Trial In HER2-Amplified Biliary Tract Cancer In Asia In Collaboration With BeiGene   Benzinga
Nov 30, 2020
08:38AM EST  Zymeworks Gets FDA Breakthrough Therapy Designation For Zanidatamab In Patients With Biliary Tract Cancer   RTTNews
08:35AM EST  Zymeworks Receives FDA Breakthrough Therapy Designation For HER2-Targeted Bispecific Antibody Zanidatamab In Patients With Biliary Tract Cancer   Benzinga
Nov 19, 2020
08:37AM EST  Zymeworks Receives Orphan Drug Designation From The European Commission For HER2-Targeted Bispecific Antibody Zanidatamab In Patients With Gastric Cancer   Benzinga
Nov 18, 2020
07:30AM EST  The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted   Benzinga
Nov 17, 2020
08:32AM EST  The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration   Benzinga
Nov 16, 2020
04:17PM EST  Zymeworks, ALX Oncology Report Clinical Collaboration Evaluating Zanidatamab With CD47 Blocker ALX148 In Patients With Advanced HER2-Expressing Breast Cancer   Benzinga
04:16PM EST  Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2?Expressing Breast Cancer   Business Wire
Nov 10, 2020
08:30AM EST  Zymeworks to Present at Upcoming Investor Conferences   Business Wire
Nov 3, 2020
04:20PM EST  Zymeworks Q3 EPS $(1.06) Down From $(0.54) YoY, Sales $2.60M Down From $7.86M YoY   Benzinga
04:16PM EST  Zymeworks Q3 EPS $(1.06) Down From $(0.54) YoY   Benzinga
04:15PM EST  Zymeworks Reports 2020 Third Quarter Financial Results   Business Wire
Sep 17, 2020
07:44AM EDT  ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration With Zymeworks   RTTNews
Sep 11, 2020
10:24AM EDT  Shares of Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company, are currently trading at $37.09, up $4.57 or 14.05% Friday morning, with trading volume of 416K more shares versus an average volume of 388K shares. There is no company specific news that could be attributed to today's stock movement.   RTTNews
Sep 3, 2020
08:30AM EDT  Zymeworks to Present at Upcoming Investor Conferences   Business Wire
Aug 6, 2020
02:44PM EDT  Benzinga's Top Upgrades, Downgrades For August 6, 2020   Benzinga
06:34AM EDT  SVB Leerink Initiates Coverage On Zymeworks with Outperform Rating, Announces Price Target of $45   Benzinga
Aug 5, 2020
05:23PM EDT  Zymeworks Q2 EPS $(0.63) Down From $(0.61) YoY, Sales $12.36M Up From $7.88M YoY   Benzinga
04:16PM EDT  Zymeworks Reports 2020 Second Quarter Financial Results   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC